Worldquant Millennium Advisors LLC Has $46.45 Million Stock Holdings in Agilent Technologies, Inc. (NYSE:A)

Worldquant Millennium Advisors LLC grew its holdings in Agilent Technologies, Inc. (NYSE:A - Free Report) by 3.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 345,791 shares of the medical research company's stock after purchasing an additional 12,757 shares during the quarter. Worldquant Millennium Advisors LLC owned about 0.12% of Agilent Technologies worth $46,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in A. Wellington Management Group LLP raised its stake in Agilent Technologies by 0.6% during the 4th quarter. Wellington Management Group LLP now owns 9,306,805 shares of the medical research company's stock worth $1,250,276,000 after buying an additional 59,781 shares during the period. Geode Capital Management LLC raised its stake in shares of Agilent Technologies by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 7,002,671 shares of the medical research company's stock worth $938,291,000 after purchasing an additional 53,992 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in shares of Agilent Technologies by 0.9% in the fourth quarter. Pictet Asset Management Holding SA now owns 5,213,739 shares of the medical research company's stock worth $700,414,000 after purchasing an additional 47,495 shares during the last quarter. Deutsche Bank AG raised its stake in shares of Agilent Technologies by 0.9% in the fourth quarter. Deutsche Bank AG now owns 4,436,700 shares of the medical research company's stock worth $596,026,000 after purchasing an additional 38,348 shares during the last quarter. Finally, Northern Trust Corp raised its stake in shares of Agilent Technologies by 12.3% in the fourth quarter. Northern Trust Corp now owns 4,192,790 shares of the medical research company's stock worth $563,259,000 after purchasing an additional 457,713 shares during the last quarter.

Agilent Technologies Trading Down 0.4%

Shares of A stock opened at $113.32 on Tuesday. The company has a quick ratio of 1.66, a current ratio of 2.20 and a debt-to-equity ratio of 0.56. The business has a 50-day moving average price of $110.31 and a two-hundred day moving average price of $127.99. Agilent Technologies, Inc. has a 12-month low of $96.43 and a 12-month high of $154.95. The firm has a market cap of $32.31 billion, a P/E ratio of 26.05, a price-to-earnings-growth ratio of 3.21 and a beta of 1.27.

Agilent Technologies (NYSE:A - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The firm had revenue of $1.68 billion during the quarter, compared to analyst estimates of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%. Equities analysts anticipate that Agilent Technologies, Inc. will post 5.54 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 23rd. Stockholders of record on Tuesday, April 1st were issued a $0.248 dividend. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.88%. Agilent Technologies's dividend payout ratio is currently 22.76%.

Analyst Ratings Changes

A has been the subject of several analyst reports. Wells Fargo & Company lowered their price objective on Agilent Technologies from $155.00 to $135.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. TD Cowen increased their price objective on Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research note on Thursday, April 10th. Barclays decreased their price target on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Jefferies Financial Group decreased their price target on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research report on Monday, April 21st. Finally, Robert W. Baird decreased their price target on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating for the company in a research report on Thursday, February 27th. Seven investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $143.00.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the sale, the director now directly owns 35,737 shares of the company's stock, valued at approximately $4,161,931.02. The trade was a 4.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Rodney Gonsalves sold 1,908 shares of Agilent Technologies stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the sale, the vice president now directly owns 21,786 shares in the company, valued at approximately $2,657,456.28. The trade was a 8.05% decrease in their ownership of the stock. The disclosure for this sale can be found here.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.